Anavex Life Sciences Corp (AVXL)

[sokol]

Rett syndrome is a rare genetic postnatal neurological disorder of the grey matter of the brain that almost exclusively affects females but has also been found in male patients. The clinical features include small hands and feet and a deceleration of the rate of head growth (including microcephaly in some). (Paraphrased from Wikipedia).

Onset occurs between 6 and 18 months of age. It is a horrible disease. There is no cure.

Three reasons for Anavex to move on Rhett syndrome are: 1. Funding is more likely to be available. 2. It is a rare disease (fast track). 3. There is no cure (fast track).

I believe that fast track development is virtually guaranteed.

It is interesting to note microcephaly is a feature in some victims. With the Zika virus rapidly developing, microcephaly will be on the increase. Query: If AVXL-273 works to treat Rhett syndrome, will it work to treat microcephaly?